Nature News

CD24 signaling by Siglec-10 macrophage is a goal for most cancers immunotherapy

1.

Majeti, R. et al. CD47 is an hostile prognostic issue and a therapeutic antibody goal on human stem cells of acute myeloid leukemia. Cell 138, 286-299 (2009).

2

Gordon, S. R. et al. Expression of PD-1 by macrophages related to the tumor inhibits phagocytosis and tumor immunity. Nature 545, 495-499 (2017).

three

Barkal, A.A. et al. Class I MHC binding by the LILRB1 inhibitory receptor suppresses macrophages and is a goal of most cancers immunotherapy. Nat. Immunol. 19, 76-84 (2018).

four

Advani, R. et al. Blockade of CD47 by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma. N. Engl. J. Med. 379, 1711-1721 (2018).

5

Willingham, S.B. et al. The interplay of the sign alpha regulatory protein CD47 (SIRPa) is a therapeutic goal for human stable tumors. Proc. Natl Acad. Sci. USA 109, 6662-6667 (2012).

6

Pirruccello, S.J. and LeBien, T.W. The B-cell related CD24 antigen is a single chain sialoglycoprotein. J. Immunol. 136, 3779-3784 (1986).

7.

Chen, G.Y., Brown, N.Ok., Zheng, P. and Liu, Y. Siglec-G / 10 within the context of discrimination between self and innate and adaptive immunity. Glycobiology 24, 800-806 (2014).

eight

Chen, W. et al. The induction of Siglec-G by RNA viruses inhibits the innate immune response by selling the degradation of RIG-I. Cell 152, 467-478 (2013).

9

Chen, G. Y. et al. Enchancment of sepsis by inhibiting the interruption of the sialidase-induced CD24-SiglecG interplay. Nat. Biotechnol. 29, 428-435 (2011).

ten.

Chen, G. Y., Tang, J., Zheng, P. and Liu, Y. CD24 and Siglec-10 selectively suppress the immune responses induced by tissue lesions. Science 323, 1722-1725 (2009).

11

Toubai, T. et al. The Siglec-G-CD24 axis controls the severity of graft-versus-host illness in mice. Blood 123, 3512-3523 (2014).

12

Crocker, P.R., Paulson, J.C. and Varki, A. Siglecs and their roles within the immune system. Nat. Rev. Immunol. 7, 255-266 (2007).

13

Abram, C.L. & Lowell, C.A. Shp1 perform in myeloid cells. J. Leukoc. Biol. 102, 657-675 (2017).

14

Dietrich, J., Cella, M. and Colonna, M. The Ig-like transcript 2 (ILT2) / Ig-leukocyte-like receptor 1 (LIR1) inhibits TCR signaling and the reorganization of the cytoskeleton. ; actin. J. Immunol. 166, 2514-2521 (2001).

15

Tarhriz, V. et al. Overview of CD24 as a brand new molecular marker in ovarian most cancers. J. Cell. Physiol. 234, 2134-2142 (2019).

16

Kristiansen, G. et al. The expression of CD24 is a brand new prognostic marker for breast most cancers. Clin. Most cancers Res. 9, 4906-4913 (2003).

17

Karaayvaz, M. et al. Unravel subclonal heterogeneity and aggressive illness states in TNBC through RNA-seq. Nat. Widespread. 9, 3588 (2018).

18

Mantovani, A., S. Sozzani, M. Locati, Allavena, P. and Sica, A. Polarization of macrophages: tumor-associated macrophages as a paradigm of polarized M2 mononuclear phagocytes. Tendencies Immunol. 23, 549-555 (2002).

19

Liu, J. et al. Preclinical improvement of a humanized anti-CD47 antibody with anticancer therapeutic potential. PLoS ONE 10, e0137345 (2015).

20

Miksa, M., Komura, H., Wu, R., Shah, KG and Wang, P. A brand new technique for figuring out the burial of apoptotic cells by macrophages utilizing the identical technique. ester of pH succinimidyl. J. Immunol. Strategies 342, 71-77 (2009).

21

Okazaki, M., Luo, Y., Han, T., Yoshida, M. and Seon, BK Three new monoclonal antibodies that outline a single antigen related to prolymphocytic leukemia / non-Hodgkin's lymphoma and are literally internalized after binding to the cell. floor antigen. Blood 81, 84-94 (1993).

22

Shultz, L. D. et al. Improvement of lymphoid and myeloid cells in NOD / LtSz-scid IL2R null γ mice grafted with mobilized human hematopoietic stem cells. J. Immunol. 174, 6477-6489 (2005).

23

Varga A. et al. Pembrolizumab in sufferers (pts) with superior PD-L1-positive ovarian most cancers (PD-L1 +): Up to date evaluation of KEYNOTE-Zero28. J. Clin. Oncol. 35, 5513 (2017).

24

Nanda, R. et al. Pebrolizumab in sufferers with superior triple detrimental breast most cancers: Section Ib examine KEYNOTE-Zero12. J. Clin. Oncol. 34, 2460-2677 (2016).

25

Alsaab, H. O. et al. PD-1 and PD-L1 inhibiting management level signaling for most cancers immunotherapy: mechanism, combos and scientific outcomes. Entrance. Pharmacol. eight, 561 (2017).

26

Ayers M. et al. Molecular profile of cohorts of tumor samples to information the scientific improvement of pembrolizumab monotherapy. Medical Most cancers Res. https://doi.org/10.1158/1078-0432.CCR-18-1316 (2018).

27

Goldman, M., Craft, B., Brooks, A.N., Zhu, J. and Haussler, D. USCS Xena Platform for the Visualization and Interpretation of Most cancers Genomic Information. Preprint on https://doi.org/10.1101/326470v3 (2018).

28

Martinez, F. O. Evaluation of Gene Expression and Gene Silencing in Human Macrophages. Curr. Protoc. Immunol. 96, 14.28.1-14.28.23 (2012)

29

Brinkman, E. Ok., Chen T., Amendola, M. and van Steensel, B. Simple quantitative analysis of genome modifying by sequence hint decomposition. Nucleic Acids Res. 42, e168 (2014).

Leave a Reply

Your email address will not be published. Required fields are marked *